nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ALB—acquired immunodeficiency syndrome	0.228	1	CbGaD
Vismodegib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0373	0.063	CbGbCtD
Vismodegib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0251	0.0425	CbGbCtD
Vismodegib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0227	0.0385	CbGbCtD
Vismodegib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0227	0.0385	CbGbCtD
Vismodegib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0218	0.0369	CbGbCtD
Vismodegib—SHH—secondary palate—acquired immunodeficiency syndrome	0.0212	0.352	CbGeAlD
Vismodegib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0169	0.0285	CbGbCtD
Vismodegib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.016	0.027	CbGbCtD
Vismodegib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.016	0.027	CbGbCtD
Vismodegib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0158	0.0267	CbGbCtD
Vismodegib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0157	0.0265	CbGbCtD
Vismodegib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.015	0.0254	CbGbCtD
Vismodegib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0148	0.0251	CbGbCtD
Vismodegib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0134	0.0227	CbGbCtD
Vismodegib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0134	0.0227	CbGbCtD
Vismodegib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0131	0.0222	CbGbCtD
Vismodegib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0123	0.0208	CbGbCtD
Vismodegib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0123	0.0208	CbGbCtD
Vismodegib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0121	0.0205	CbGbCtD
Vismodegib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0121	0.0205	CbGbCtD
Vismodegib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.012	0.0202	CbGbCtD
Vismodegib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0116	0.0196	CbGbCtD
Vismodegib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0116	0.0196	CbGbCtD
Vismodegib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0112	0.019	CbGbCtD
Vismodegib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0111	0.0189	CbGbCtD
Vismodegib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0111	0.0189	CbGbCtD
Vismodegib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0183	CbGbCtD
Vismodegib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0102	0.0172	CbGbCtD
Vismodegib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0102	0.0172	CbGbCtD
Vismodegib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00974	0.0165	CbGbCtD
Vismodegib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00962	0.0163	CbGbCtD
Vismodegib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00934	0.0158	CbGbCtD
Vismodegib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00934	0.0158	CbGbCtD
Vismodegib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00907	0.0153	CbGbCtD
Vismodegib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00845	0.0143	CbGbCtD
Vismodegib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00845	0.0143	CbGbCtD
Vismodegib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0082	0.0139	CbGbCtD
Vismodegib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0082	0.0139	CbGbCtD
Vismodegib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0081	0.0137	CbGbCtD
Vismodegib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00786	0.0133	CbGbCtD
Vismodegib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00762	0.0129	CbGbCtD
Vismodegib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00717	0.0121	CbGbCtD
Vismodegib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00717	0.0121	CbGbCtD
Vismodegib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00648	0.011	CbGbCtD
Vismodegib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00648	0.011	CbGbCtD
Vismodegib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00608	0.0103	CbGbCtD
Vismodegib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0056	0.00946	CbGbCtD
Vismodegib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00543	0.00919	CbGbCtD
Vismodegib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00491	0.00831	CbGbCtD
Vismodegib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00491	0.00831	CbGbCtD
Vismodegib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00471	0.00796	CbGbCtD
Vismodegib—ORM1—saliva—acquired immunodeficiency syndrome	0.00333	0.0553	CbGeAlD
Vismodegib—SHH—skin of body—acquired immunodeficiency syndrome	0.00228	0.0379	CbGeAlD
Vismodegib—SHH—digestive system—acquired immunodeficiency syndrome	0.00182	0.0303	CbGeAlD
Vismodegib—SHH—bone marrow—acquired immunodeficiency syndrome	0.00168	0.0279	CbGeAlD
Vismodegib—SHH—spinal cord—acquired immunodeficiency syndrome	0.00167	0.0278	CbGeAlD
Vismodegib—SMO—skin of body—acquired immunodeficiency syndrome	0.00159	0.0265	CbGeAlD
Vismodegib—SHH—lung—acquired immunodeficiency syndrome	0.00152	0.0253	CbGeAlD
Vismodegib—SHH—nervous system—acquired immunodeficiency syndrome	0.00141	0.0234	CbGeAlD
Vismodegib—SHH—central nervous system—acquired immunodeficiency syndrome	0.00136	0.0225	CbGeAlD
Vismodegib—SMO—spinal cord—acquired immunodeficiency syndrome	0.00117	0.0194	CbGeAlD
Vismodegib—SMO—vagina—acquired immunodeficiency syndrome	0.00113	0.0187	CbGeAlD
Vismodegib—SHH—brain—acquired immunodeficiency syndrome	0.00108	0.0179	CbGeAlD
Vismodegib—SMO—lung—acquired immunodeficiency syndrome	0.00106	0.0177	CbGeAlD
Vismodegib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00102	0.017	CbGeAlD
Vismodegib—SMO—nervous system—acquired immunodeficiency syndrome	0.000986	0.0164	CbGeAlD
Vismodegib—SMO—central nervous system—acquired immunodeficiency syndrome	0.000949	0.0158	CbGeAlD
Vismodegib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000893	0.0148	CbGeAlD
Vismodegib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000793	0.0132	CbGeAlD
Vismodegib—SMO—brain—acquired immunodeficiency syndrome	0.000754	0.0125	CbGeAlD
Vismodegib—SMO—lymph node—acquired immunodeficiency syndrome	0.000728	0.0121	CbGeAlD
Vismodegib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000605	0.01	CbGeAlD
Vismodegib—ORM1—blood—acquired immunodeficiency syndrome	0.000531	0.00882	CbGeAlD
Vismodegib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000514	0.00853	CbGeAlD
Vismodegib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000511	0.00849	CbGeAlD
Vismodegib—ORM1—lung—acquired immunodeficiency syndrome	0.000465	0.00773	CbGeAlD
Vismodegib—ORM1—nervous system—acquired immunodeficiency syndrome	0.000431	0.00716	CbGeAlD
Vismodegib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000428	0.00711	CbGeAlD
Vismodegib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000415	0.00689	CbGeAlD
Vismodegib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000393	0.00653	CbGeAlD
Vismodegib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000375	0.00623	CbGeAlD
Vismodegib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000347	0.00577	CbGeAlD
Vismodegib—Dysgeusia—Indinavir—acquired immunodeficiency syndrome	0.000327	0.00278	CcSEcCtD
Vismodegib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000327	0.00543	CbGeAlD
Vismodegib—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.000326	0.00277	CcSEcCtD
Vismodegib—Back pain—Indinavir—acquired immunodeficiency syndrome	0.000323	0.00275	CcSEcCtD
Vismodegib—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000323	0.00275	CcSEcCtD
Vismodegib—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.000321	0.00273	CcSEcCtD
Vismodegib—Alopecia—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.00273	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.000318	0.00271	CcSEcCtD
Vismodegib—ORM1—lymph node—acquired immunodeficiency syndrome	0.000318	0.00529	CbGeAlD
Vismodegib—ABCG2—blood—acquired immunodeficiency syndrome	0.000318	0.00528	CbGeAlD
Vismodegib—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.000318	0.0027	CcSEcCtD
Vismodegib—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000316	0.00268	CcSEcCtD
Vismodegib—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.000315	0.00268	CcSEcCtD
Vismodegib—Dysgeusia—Efavirenz—acquired immunodeficiency syndrome	0.000309	0.00263	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.000308	0.00262	CcSEcCtD
Vismodegib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000308	0.00511	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.000307	0.00261	CcSEcCtD
Vismodegib—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.000307	0.00261	CcSEcCtD
Vismodegib—Alopecia—Delavirdine—acquired immunodeficiency syndrome	0.000307	0.00261	CcSEcCtD
Vismodegib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000306	0.00509	CbGeAlD
Vismodegib—Myalgia—Zidovudine—acquired immunodeficiency syndrome	0.000306	0.0026	CcSEcCtD
Vismodegib—Arthralgia—Zidovudine—acquired immunodeficiency syndrome	0.000306	0.0026	CcSEcCtD
Vismodegib—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000306	0.0026	CcSEcCtD
Vismodegib—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.000305	0.0026	CcSEcCtD
Vismodegib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000305	0.00507	CbGeAlD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000304	0.00258	CcSEcCtD
Vismodegib—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.000304	0.00258	CcSEcCtD
Vismodegib—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.000304	0.00258	CcSEcCtD
Vismodegib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000303	0.00504	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.000303	0.00258	CcSEcCtD
Vismodegib—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000302	0.00257	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000302	0.00257	CcSEcCtD
Vismodegib—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000302	0.00256	CcSEcCtD
Vismodegib—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000301	0.00256	CcSEcCtD
Vismodegib—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000299	0.00254	CcSEcCtD
Vismodegib—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.000298	0.00253	CcSEcCtD
Vismodegib—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000297	0.00253	CcSEcCtD
Vismodegib—Dysgeusia—Delavirdine—acquired immunodeficiency syndrome	0.000296	0.00252	CcSEcCtD
Vismodegib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000295	0.0049	CbGeAlD
Vismodegib—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000294	0.0025	CcSEcCtD
Vismodegib—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000293	0.00249	CcSEcCtD
Vismodegib—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000292	0.00248	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000292	0.00248	CcSEcCtD
Vismodegib—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000292	0.00248	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000291	0.00248	CcSEcCtD
Vismodegib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000291	0.00247	CcSEcCtD
Vismodegib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000291	0.00483	CbGeAlD
Vismodegib—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.00029	0.00247	CcSEcCtD
Vismodegib—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.00246	CcSEcCtD
Vismodegib—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000289	0.00246	CcSEcCtD
Vismodegib—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000289	0.00246	CcSEcCtD
Vismodegib—ALB—brain—acquired immunodeficiency syndrome	0.000289	0.0048	CbGeAlD
Vismodegib—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000289	0.00245	CcSEcCtD
Vismodegib—Pain—Stavudine—acquired immunodeficiency syndrome	0.000289	0.00245	CcSEcCtD
Vismodegib—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000288	0.00245	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000287	0.00244	CcSEcCtD
Vismodegib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000287	0.00244	CcSEcCtD
Vismodegib—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000286	0.00243	CcSEcCtD
Vismodegib—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000285	0.00242	CcSEcCtD
Vismodegib—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.000284	0.00242	CcSEcCtD
Vismodegib—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000284	0.00242	CcSEcCtD
Vismodegib—Pain—Abacavir—acquired immunodeficiency syndrome	0.000284	0.00242	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000283	0.0024	CcSEcCtD
Vismodegib—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000279	0.00238	CcSEcCtD
Vismodegib—ALB—lymph node—acquired immunodeficiency syndrome	0.000279	0.00464	CbGeAlD
Vismodegib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000279	0.00237	CcSEcCtD
Vismodegib—ABCG2—lung—acquired immunodeficiency syndrome	0.000279	0.00463	CbGeAlD
Vismodegib—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000277	0.00235	CcSEcCtD
Vismodegib—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000276	0.00235	CcSEcCtD
Vismodegib—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000276	0.00235	CcSEcCtD
Vismodegib—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000275	0.00234	CcSEcCtD
Vismodegib—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.000274	0.00233	CcSEcCtD
Vismodegib—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.00232	CcSEcCtD
Vismodegib—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000272	0.00231	CcSEcCtD
Vismodegib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000271	0.0023	CcSEcCtD
Vismodegib—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.00027	0.0023	CcSEcCtD
Vismodegib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000269	0.00229	CcSEcCtD
Vismodegib—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.000269	0.00229	CcSEcCtD
Vismodegib—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000269	0.00229	CcSEcCtD
Vismodegib—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000269	0.00229	CcSEcCtD
Vismodegib—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000269	0.00228	CcSEcCtD
Vismodegib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000269	0.00228	CcSEcCtD
Vismodegib—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000268	0.00228	CcSEcCtD
Vismodegib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00227	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000267	0.00227	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000267	0.00227	CcSEcCtD
Vismodegib—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000267	0.00227	CcSEcCtD
Vismodegib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000266	0.00226	CcSEcCtD
Vismodegib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000265	0.00225	CcSEcCtD
Vismodegib—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00224	CcSEcCtD
Vismodegib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000263	0.00223	CcSEcCtD
Vismodegib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.00221	CcSEcCtD
Vismodegib—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.00221	CcSEcCtD
Vismodegib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000259	0.0022	CcSEcCtD
Vismodegib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000258	0.0022	CcSEcCtD
Vismodegib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.00219	CcSEcCtD
Vismodegib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.00219	CcSEcCtD
Vismodegib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000257	0.00218	CcSEcCtD
Vismodegib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000255	0.00217	CcSEcCtD
Vismodegib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000253	0.00215	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000253	0.00215	CcSEcCtD
Vismodegib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000253	0.00215	CcSEcCtD
Vismodegib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.00215	CcSEcCtD
Vismodegib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00214	CcSEcCtD
Vismodegib—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000251	0.00213	CcSEcCtD
Vismodegib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000251	0.00213	CcSEcCtD
Vismodegib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000251	0.00213	CcSEcCtD
Vismodegib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00025	0.00213	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000248	0.00211	CcSEcCtD
Vismodegib—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00211	CcSEcCtD
Vismodegib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000247	0.0021	CcSEcCtD
Vismodegib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000247	0.0021	CcSEcCtD
Vismodegib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000247	0.0021	CcSEcCtD
Vismodegib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000245	0.00208	CcSEcCtD
Vismodegib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000245	0.00208	CcSEcCtD
Vismodegib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000243	0.00206	CcSEcCtD
Vismodegib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000242	0.00206	CcSEcCtD
Vismodegib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00024	0.00204	CcSEcCtD
Vismodegib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00024	0.00204	CcSEcCtD
Vismodegib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000239	0.00204	CcSEcCtD
Vismodegib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000239	0.00204	CcSEcCtD
Vismodegib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000239	0.00203	CcSEcCtD
Vismodegib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000239	0.00203	CcSEcCtD
Vismodegib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000238	0.00203	CcSEcCtD
Vismodegib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.00202	CcSEcCtD
Vismodegib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.00202	CcSEcCtD
Vismodegib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000237	0.00202	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.00201	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000235	0.002	CcSEcCtD
Vismodegib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000235	0.002	CcSEcCtD
Vismodegib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000235	0.002	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000235	0.002	CcSEcCtD
Vismodegib—ABCB1—retina—acquired immunodeficiency syndrome	0.000234	0.00389	CbGeAlD
Vismodegib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000233	0.00198	CcSEcCtD
Vismodegib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000233	0.00198	CcSEcCtD
Vismodegib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000233	0.00386	CbGeAlD
Vismodegib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000232	0.00197	CcSEcCtD
Vismodegib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000232	0.00197	CcSEcCtD
Vismodegib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000231	0.00196	CcSEcCtD
Vismodegib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000231	0.00196	CcSEcCtD
Vismodegib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.00195	CcSEcCtD
Vismodegib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.00195	CcSEcCtD
Vismodegib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000227	0.00193	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.00193	CcSEcCtD
Vismodegib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.00193	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000225	0.00191	CcSEcCtD
Vismodegib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.0019	CcSEcCtD
Vismodegib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.0019	CcSEcCtD
Vismodegib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000223	0.0019	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000222	0.00189	CcSEcCtD
Vismodegib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000222	0.00189	CcSEcCtD
Vismodegib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000222	0.00189	CcSEcCtD
Vismodegib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000222	0.00368	CbGeAlD
Vismodegib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.00188	CcSEcCtD
Vismodegib—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.00187	CcSEcCtD
Vismodegib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.00187	CcSEcCtD
Vismodegib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00022	0.00187	CcSEcCtD
Vismodegib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00022	0.00187	CcSEcCtD
Vismodegib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.00186	CcSEcCtD
Vismodegib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.00186	CcSEcCtD
Vismodegib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.00185	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.00184	CcSEcCtD
Vismodegib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000216	0.00183	CcSEcCtD
Vismodegib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.00183	CcSEcCtD
Vismodegib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000215	0.00183	CcSEcCtD
Vismodegib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000215	0.00182	CcSEcCtD
Vismodegib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.00182	CcSEcCtD
Vismodegib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000213	0.00181	CcSEcCtD
Vismodegib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000211	0.0018	CcSEcCtD
Vismodegib—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000211	0.00179	CcSEcCtD
Vismodegib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000211	0.00179	CcSEcCtD
Vismodegib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000211	0.00179	CcSEcCtD
Vismodegib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00021	0.00179	CcSEcCtD
Vismodegib—Rash—Abacavir—acquired immunodeficiency syndrome	0.00021	0.00178	CcSEcCtD
Vismodegib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000209	0.00178	CcSEcCtD
Vismodegib—SMO—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.000209	0.0825	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000208	0.00177	CcSEcCtD
Vismodegib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000208	0.00177	CcSEcCtD
Vismodegib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000207	0.00176	CcSEcCtD
Vismodegib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00175	CcSEcCtD
Vismodegib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000204	0.00173	CcSEcCtD
Vismodegib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.00173	CcSEcCtD
Vismodegib—CYP2C8—brain—acquired immunodeficiency syndrome	0.000203	0.00337	CbGeAlD
Vismodegib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000202	0.00171	CcSEcCtD
Vismodegib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000201	0.00171	CcSEcCtD
Vismodegib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.00171	CcSEcCtD
Vismodegib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000201	0.00171	CcSEcCtD
Vismodegib—Nausea—Stavudine—acquired immunodeficiency syndrome	0.0002	0.0017	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.0017	CcSEcCtD
Vismodegib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.00169	CcSEcCtD
Vismodegib—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000197	0.00168	CcSEcCtD
Vismodegib—ABCG2—brain—acquired immunodeficiency syndrome	0.000197	0.00328	CbGeAlD
Vismodegib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.00167	CcSEcCtD
Vismodegib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.00167	CcSEcCtD
Vismodegib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000196	0.00166	CcSEcCtD
Vismodegib—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.00166	CcSEcCtD
Vismodegib—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.00166	CcSEcCtD
Vismodegib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000195	0.00166	CcSEcCtD
Vismodegib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.00164	CcSEcCtD
Vismodegib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000193	0.00164	CcSEcCtD
Vismodegib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.00162	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000191	0.00162	CcSEcCtD
Vismodegib—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000191	0.00317	CbGeAlD
Vismodegib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.00161	CcSEcCtD
Vismodegib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.00161	CcSEcCtD
Vismodegib—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.0016	CcSEcCtD
Vismodegib—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.0016	CcSEcCtD
Vismodegib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000187	0.00159	CcSEcCtD
Vismodegib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000186	0.00159	CcSEcCtD
Vismodegib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000186	0.00159	CcSEcCtD
Vismodegib—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000185	0.00157	CcSEcCtD
Vismodegib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000185	0.00157	CcSEcCtD
Vismodegib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000185	0.00157	CcSEcCtD
Vismodegib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.00157	CcSEcCtD
Vismodegib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000182	0.00155	CcSEcCtD
Vismodegib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.00155	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.00154	CcSEcCtD
Vismodegib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.00153	CcSEcCtD
Vismodegib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00018	0.00153	CcSEcCtD
Vismodegib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.00018	0.00299	CbGeAlD
Vismodegib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000179	0.00153	CcSEcCtD
Vismodegib—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.00152	CcSEcCtD
Vismodegib—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.00152	CcSEcCtD
Vismodegib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000177	0.0015	CcSEcCtD
Vismodegib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000176	0.0015	CcSEcCtD
Vismodegib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000174	0.00148	CcSEcCtD
Vismodegib—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000174	0.00148	CcSEcCtD
Vismodegib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000173	0.00148	CcSEcCtD
Vismodegib—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000173	0.00147	CcSEcCtD
Vismodegib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000173	0.00288	CbGeAlD
Vismodegib—Rash—Indinavir—acquired immunodeficiency syndrome	0.000172	0.00146	CcSEcCtD
Vismodegib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000172	0.00146	CcSEcCtD
Vismodegib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000171	0.00146	CcSEcCtD
Vismodegib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000169	0.00143	CcSEcCtD
Vismodegib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000167	0.00277	CbGeAlD
Vismodegib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000165	0.00141	CcSEcCtD
Vismodegib—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000165	0.00273	CbGeAlD
Vismodegib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000164	0.00139	CcSEcCtD
Vismodegib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000164	0.00139	CcSEcCtD
Vismodegib—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000162	0.00138	CcSEcCtD
Vismodegib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000162	0.00138	CcSEcCtD
Vismodegib—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000162	0.00138	CcSEcCtD
Vismodegib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000161	0.00137	CcSEcCtD
Vismodegib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.00134	CcSEcCtD
Vismodegib—ABCB1—blood—acquired immunodeficiency syndrome	0.000157	0.00261	CbGeAlD
Vismodegib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.00133	CcSEcCtD
Vismodegib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.00133	CcSEcCtD
Vismodegib—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000155	0.00132	CcSEcCtD
Vismodegib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000155	0.00132	CcSEcCtD
Vismodegib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.00132	CcSEcCtD
Vismodegib—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.0013	CcSEcCtD
Vismodegib—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000152	0.00252	CbGeAlD
Vismodegib—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000151	0.00251	CbGeAlD
Vismodegib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.00128	CcSEcCtD
Vismodegib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.00128	CcSEcCtD
Vismodegib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.00126	CcSEcCtD
Vismodegib—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.00125	CcSEcCtD
Vismodegib—ABCB1—vagina—acquired immunodeficiency syndrome	0.000145	0.00241	CbGeAlD
Vismodegib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000145	0.00123	CcSEcCtD
Vismodegib—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.00122	CcSEcCtD
Vismodegib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.00122	CcSEcCtD
Vismodegib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000143	0.00122	CcSEcCtD
Vismodegib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.00119	CcSEcCtD
Vismodegib—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.00118	CcSEcCtD
Vismodegib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.00118	CcSEcCtD
Vismodegib—ABCB1—lung—acquired immunodeficiency syndrome	0.000137	0.00228	CbGeAlD
Vismodegib—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.00115	CcSEcCtD
Vismodegib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000133	0.00113	CcSEcCtD
Vismodegib—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000132	0.00112	CcSEcCtD
Vismodegib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000132	0.00112	CcSEcCtD
Vismodegib—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.00111	CcSEcCtD
Vismodegib—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000127	0.00211	CbGeAlD
Vismodegib—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.00106	CcSEcCtD
Vismodegib—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000123	0.00204	CbGeAlD
Vismodegib—SHH—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000103	0.0407	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	9.76e-05	0.0386	CbGpPWpGaD
Vismodegib—ABCB1—brain—acquired immunodeficiency syndrome	9.73e-05	0.00162	CbGeAlD
Vismodegib—ABCB1—lymph node—acquired immunodeficiency syndrome	9.4e-05	0.00156	CbGeAlD
Vismodegib—ALB—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	8.5e-05	0.0336	CbGpPWpGaD
Vismodegib—SMO—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	7.51e-05	0.0297	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	6.24e-05	0.0247	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.91e-05	0.0234	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.64e-05	0.0223	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.35e-05	0.0211	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.28e-05	0.0209	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.01e-05	0.0198	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—IL6—acquired immunodeficiency syndrome	4.49e-05	0.0177	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.85e-05	0.0152	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.65e-05	0.0144	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	3.56e-05	0.0141	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	3.56e-05	0.0141	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.0138	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.3e-05	0.0131	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.28e-05	0.013	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.28e-05	0.013	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.2e-05	0.0127	CbGpPWpGaD
Vismodegib—SHH—Disease—APOBEC3G—acquired immunodeficiency syndrome	3.18e-05	0.0126	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.12e-05	0.0123	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.11e-05	0.0123	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.11e-05	0.0123	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.03e-05	0.012	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.96e-05	0.0117	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.89e-05	0.0114	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.74e-05	0.0109	CbGpPWpGaD
Vismodegib—SHH—Disease—CCNT1—acquired immunodeficiency syndrome	2.7e-05	0.0107	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.49e-05	0.00986	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.36e-05	0.00934	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.25e-05	0.00888	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.13e-05	0.00842	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	2.05e-05	0.00811	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.98e-05	0.00782	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	1.92e-05	0.0076	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	1.92e-05	0.0076	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.89e-05	0.00748	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.89e-05	0.00748	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.87e-05	0.00741	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.84e-05	0.00728	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.79e-05	0.00709	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.79e-05	0.00709	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.79e-05	0.00707	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.75e-05	0.00691	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.71e-05	0.00676	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.7e-05	0.0067	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.68e-05	0.00665	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.68e-05	0.00665	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	1.67e-05	0.00659	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.62e-05	0.00641	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	1.62e-05	0.0064	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.59e-05	0.0063	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.59e-05	0.0063	CbGpPWpGaD
Vismodegib—SHH—Disease—CXCR4—acquired immunodeficiency syndrome	1.42e-05	0.00561	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.28e-05	0.00506	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	1.26e-05	0.00499	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	1.26e-05	0.00499	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.26e-05	0.00498	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	1.23e-05	0.00485	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.00479	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	1.2e-05	0.00475	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	1.2e-05	0.00475	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.00472	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.17e-05	0.00462	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.15e-05	0.00456	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.11e-05	0.00438	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.00432	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.06e-05	0.00418	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1e-05	0.00396	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.93e-06	0.00393	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.93e-06	0.00393	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	9.78e-06	0.00387	CbGpPWpGaD
Vismodegib—SHH—Disease—CCR5—acquired immunodeficiency syndrome	9.72e-06	0.00384	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.42e-06	0.00372	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.42e-06	0.00372	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.38e-06	0.00371	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.33e-06	0.00369	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	8.69e-06	0.00344	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.37e-06	0.00331	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	7.92e-06	0.00313	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	7.78e-06	0.00308	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	7.77e-06	0.00307	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.63e-06	0.00302	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.56e-06	0.00299	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.44e-06	0.00294	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	7.42e-06	0.00293	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.16e-06	0.00283	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.06e-06	0.00279	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.81e-06	0.00269	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	6.73e-06	0.00266	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.66e-06	0.00263	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	6.6e-06	0.00261	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.45e-06	0.00255	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	6.33e-06	0.0025	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.31e-06	0.0025	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	6.28e-06	0.00248	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	6.26e-06	0.00247	CbGpPWpGaD
Vismodegib—SHH—Disease—CD4—acquired immunodeficiency syndrome	6.1e-06	0.00241	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	5.11e-06	0.00202	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	5.03e-06	0.00199	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	4.91e-06	0.00194	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	4.89e-06	0.00193	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	4.8e-06	0.0019	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	4.39e-06	0.00173	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	4.28e-06	0.00169	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	4.18e-06	0.00165	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	4.15e-06	0.00164	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	4.12e-06	0.00163	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.06e-06	0.0016	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	4e-06	0.00158	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.93e-06	0.00156	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.91e-06	0.00155	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	3.73e-06	0.00147	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.73e-06	0.00147	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.71e-06	0.00147	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.64e-06	0.00144	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	3.4e-06	0.00134	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.31e-06	0.00131	CbGpPWpGaD
Vismodegib—SHH—Disease—IL6—acquired immunodeficiency syndrome	3.3e-06	0.00131	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	3.22e-06	0.00127	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.95e-06	0.00117	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.64e-06	0.00104	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.37e-06	0.000937	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.31e-06	0.000914	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.24e-06	0.000887	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.19e-06	0.000867	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.92e-06	0.000761	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.72e-06	0.000679	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	1.7e-06	0.000674	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.59e-06	0.00063	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.57e-06	0.000619	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	1.38e-06	0.000546	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	8.57e-07	0.000339	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	7.65e-07	0.000302	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	7.46e-07	0.000295	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	6.97e-07	0.000276	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	4.6e-07	0.000182	CbGpPWpGaD
